2026 European NF Conference

12-14 November, Vienna, Austria

EuNF2026Vienna.com

Programme

Patient involvement in Neurofibromatosis care and research

Venue:
Hyatt Regency Vienna




Hosted and sponsored by: NF Kinder

Scientific partner: MEDICAL UNIVERSITY OF VIENNA

Endorsed by: EUROPEAN NF GROUP; NF Patients United; CHILDREN'S TUMOR FOUNDATION ENDING NF THROUGH RESEARCH; European Reference Networks

Floorplan



A-D: Exhibition Booths

Table of contents

Welcome Words by the Conference Chairs 2

Official Partners and Endorsements, Organising Committee 3

Invited Speakers and Chairpersons, Reviewers 4

General Information 5

Social Events 8

Keynote Talks 9

Conference Programme Overview 11

Presentations Overview 14

List of Posters 27

Sponsors 37

Industry Exhibition 38

Industry Symposia 41



Welcome to the 2026 European Neurofibromatosis Conference!

We are delighted to invite you to the **2026 European Neurofibromatosis Conference,** taking place in **Vienna, Austria,** from **12 to 14 November 2026,** at the elegant **Hyatt Regency Vienna.**

The 2026 European Neurofibromatosis conference will focus on **patient involvement in Neurofibromatosis research and care,** bringing together leading experts, clinicians, researchers, and patient representatives from across Europe and beyond. Organised in close collaboration between the **patient organisation NF Kinder** and the **Medical University of Vienna,** the event reflects the strong partnership between science and the patient community driving progress in this field.

Together, we will explore the latest advances in understanding and managing **Neurofibromatosis type 1, NF2-related and non-related Schwannomatosis,** and discuss how collaborative approaches can improve both scientific progress and patient outcomes.

Vienna, at the heart of Europe, offers an inspiring setting for exchange and innovation. Known for its outstanding infrastructure, rich cultural heritage, and welcoming atmosphere, the city provides the ideal backdrop for a memorable scientific event. The **Hyatt Regency Vienna,** our conference venue, combines contemporary design with first-class facilities and is ideally located in the heart of Vienna, close to the historic Belvedere Palace and the main railway station.

The scientific programme will include **keynote lectures, and scientific sessions** covering patient-centred care and psychosocial aspects, collaborative research models integrating patients, clinicians, and scientists, recent advances in molecular and clinical research on NF1 and Schwannomatosis, and emerging therapies and precision medicine approaches.

We expect around **550 participants,** including **scientists, healthcare professionals, and patient advocates as well as industry partners.** The conference will provide an open and collegial environment to exchange knowledge, present new findings, and strengthen collaboration within the international Neurofibromatosis community.

We warmly invite you to participate in this unique event — as a **delegate, speaker, or poster presenter** — and to contribute to advancing **Neurofibromatosis and Schwannomatosis research** through collaboration and patient involvement.

Vienna's vibrant atmosphere, combined with a rich scientific programme and inspiring social activities, will make the **2026 European Neurofibromatosis Conference** an unforgettable experience. We are welcoming you in Vienna!



Ing. Claas Röhl
Patient Association
NF Kinder



Assoc. Prof. Dr. Amedeo Azizi
Medical University
of Vienna

Official Partners and Endorsements

Hosted by: NF Kinder

Scientific partner: MEDICAL UNIVERSITY OF VIENNA

Endorsed by: EUROPEAN NF GROUP; NF Patients United; European Reference Networks; CHILDREN'S TUMOR FOUNDATION ENDING NF THROUGH RESEARCH

Funded by: MEETING DESTINATION VIENNA

Scientific Programme Committee

Clinical Science



Amedeo Azizi (AT)



Laura Fertitta (FR)

Basic Science



Katharina Wimmer (AT)



Eduard Serra (ES)

Patient Advocate



Claas Röhl (AT)



Gilles Atlan (UK / IL)

Invited Speakers and Chairpersons

We thank our faculty members for their engagement in preparing the sessions and managing their onsite duties. You can find further information on the invited speakers here: eunf2026vienna.com/programme/invited-speakers

Igor Adameyko
Gilles Atlan
Amedeo Azizi
Arianna Baggiolini
Hilde Brems
Riccardo Buttarelli
Céline Colnot
Andreu Coy
Gareth Evans
Said Chosro Farschtschi
Rosalie Ferner
Laura Fertitta
Bernat Gel Moreno
Rachel Giles
Johannes Gojo
Gregor Kasprian
Michel Kalamarides
Magdalena Koczkowska
Iwo Korycinski
Catena Kresbach
Eric Legius
Ulrike Leiss
Vera Lipkovskaya
Kimberley McCoy
Vanessa L. Merker
Helen Morrisson
Christian Oberdanner
Rianne Oostenbrink
Enrico Opocher
Scott R. Plotkin
Christof Radler
Andre Rietman
Bernhard Robl
Claas Röhl
Anna Sablina
Herb Sarnoff
Eduard Serra Arenas
Priya Sharma
Miriam Smith
Piotr Topilko
Eva Trevisson
Daan van Dorp
Santiago Vernia
Lennart Well
Katharina Wimmer
Pierre Wolkenstein

Reviewers

EUNF herewith thanks the following persons for their timely commitment, expertise, and valuable contribution to the 2026 European NF Conference by serving as Reviewer.

Amedeo Azizi
Andre Rietman
Anna Sablina
Arianna Baggiolini
Bernat Gel Moreno
Bernhard Robl
Brigitte Widemann
Catena Kresbach
Céline Colnot
Chelsea Kotch
Christof Radler
Claas Röhl
Eduard Serra Arenas
Enrico Opocher
Eric Legius
Eva Dombi
Eva Trevisson
Gareth Evans
Gilles Atlan
Helen Morrisson
João Passos
Katharina Wimmer
Katharina Wimmer
Kerstin Krottendorfer
Laura Fertitta
Laura Klesse
Lennart Well
Magda Koczkowska
Meena Upadhyaya
Miriam Smith
Pierre Wolkenstein
Piotr Topilko
Rachel Giles
Rianne Oostenbrink
Rosalie E. Ferner
Santiago Vernia
Scott R. Plotkin
Suren Armeni Jengojan
Verena Rosenmayr
Walter Taal

General Information

Abstracts
Accepted abstracts are either presented orally during one of the scientific sessions or as set up as posters in the poster area (with no oral presentation). Abstracts are listed in this Programme Book and online.

Awards
The best posters will be awarded, followed by the presentation of the Lifetime Achievement Award and the announcement of the two winners of the prestigious Theodor Schwann Award.

Badge
Please wear your name badge at all times throughout the conference venue and during all social events. Access to the conference and social events cannot be granted without a name badge.

Your name badge is also required for scanning your CME credits. For further information, please refer to the > *CME Credit Procedure*.

Lost or forgotten name badges will be charged in full.

Catering
Non-alcoholic drinks and light snacks will be served in designated areas during the coffee breaks scheduled in the conference programme overview.

On 13 and 14 November, lunch bags containing cold food will be provided. These can be enjoyed during the two dedicated Industry Symposia scheduled on each of these days.

Vienna is renowned for the excellent quality of its tap water, which is safe and delicious to drink. We encourage you to bring your own reusable water bottle and refill it throughout the day.

Certificate of Attendance
Your certificate of attendance stating the conference date and place will be sent to you directly via email after the conference.

Cloakroom
There is a cloakroom available free of charge next to Lecture Hall 2.
> *refer to Opening Times*

CME Certificate
A maximum of 19 credits can be granted.
A CME certificate will be issued to the delegate ticket holders who fulfil the CME credit procedure (see next paragraph). The CME certificate will be sent directly via email.

CME Credit Procedure
Every participant who wants to apply for CME credits, has to scan his/her name badge at the provided CME scanning stations in the congress venue (conference level, opposite to the registration desk) every day on THU, FRI, and SAT. After the conference, the provided conference survey has to be completed online. The CME certificate will be sent directly via email no later than 4 weeks after the conference.

Emergency Telephone Numbers
Euro Emergency Call: 112
Firefighters: 122
Police: 133
Ambulance/Emergency: 144

Exhibition
The industry exhibition is located in the foyers of the conference area (as indicated on the floorplan on page 41). You can find all related information including the details of the sponsored industry symposia at the end of this booklet.

Language
The official congress language is English. There will be no simultaneous translation.

Lost and Found
Enquiries regarding lost or found items can be made at the registration desk in the congress venue.

Opening Times

Registration Desk
The registration desk is opened during the following times:

Thursday, November 12	10:00 – 21:00
Friday, November 13	06:30 – 18:00
Saturday, November 14	07:30 – 18:30

Speaker Preview Room

Thursday, November 12	09:00 – 18:00
Friday, November 13	07:00 – 18:00
Saturday, November 14	07:00 – 17:00

Poster Area

Thursday, November 12	14:30 – 21:00
Friday, November 13	07:00 – 18:00
Saturday, November 14	08:00 – 16:45

Exhibition

Thursday, November 12	12:00 – 21:00
Friday, November 13	07:00 – 18:00
Saturday, November 14	08:00 – 18:00

Cloakroom

Thursday, November 12	07:30 – 21:00
Friday, November 13	06:45 – 18:15
Saturday, November 14	07:30 – 18:30

Overflow
Two additional rooms ("Artist" and "Architect"; see floor plan, page 41) will be available to accommodate overflow from the main session halls. Depending on attendance and demand, the Organising Committee will decide on the day which session will be streamed to the overflow rooms. This flexible arrangement will help accommodate participants and ensure that sessions can be followed comfortably when the main halls reach capacity.

Photography & Recording Policy
Audio or video recording is not permitted anywhere within the conference areas unless prior written authorisation has been granted by the EUNF Organising Committee.

The official EUNF photographer is authorised to take photographs during the congress, including images of attendees. These photographs may be used in future EUNF conference materials, including preliminary and final programmes and other congress-related publications. A selection of photographs will also be made available on the official congress website.

Poster Area
The poster area is located on the right-hand side as you enter the conference area in the "Upper Belvedere". You are welcome to visit it throughout conference opening hours and during the Welcome Reception.
> *refer to Opening Times*

Registration
The registration desk is your first point of contact. Please feel free to reach out to us at any time if you have any questions.
> *refer to Opening Times*

Smoking Policy
Smoking is only allowed in designated outside areas.

Speaker Preview Room
The Speaker Preview Room is located in the room "Tailor", next to the Poster Area.
All speakers are requested to upload their presentations in the Speaker Preview Room at least 2 hours before the start of their scheduled session.
> *refer to Opening Times*

Taxi
Several taxi services operate in Vienna. One of the main providers is Taxi 40100, which can be reached by phone at +43 1 40100 or booked online. Another option is Vienna Taxi, available at +43 1 300 300. Uber and Bolt also operate in Vienna.

Venue

Address:
Hyatt Regency Vienna, Arsenalstraße 10,
1010 Vienna, Austria.
Telephone: +43 1 20577441234

The conference venue can easily be reached by public transport.

Train: Wien Hauptbahnhof (Exit via Karl-Popper-Straße)

Underground: U1 Südtiroler Platz/ Hauptbahnhof (Exit via Karl-Popper-Straße)
Streetcar (Tram): 18, D and O at station Quartier Belvedere

From both stations you can reach the conference venue in a few minutes by foot.

More information regarding public transport and arriving in Vienna can be found here:
eunf2026vienna.com/attend/getting-to-vienna

Welcome Reception

The Welcome Reception including drinks and food will take place on Thursday, November 12, at 18:30-21:00 in the foyers of the Congress Venue. It is open to all registered congress participants. Please wear your name badge.

WiFi / Internet

Free WiFi is available throughout all official congress areas. Please note that the available bandwidth is limited and intended for basic use, such as checking emails and browsing the web.

Network: **EUNF2026**
Password: **Vienna2026**



Social Events

Welcome Reception

> Hyatt Regency Vienna,
Arsenalstraße 10, 1010 Vienna, Austria

Thursday, November 12, 2026

18:30 – 21:00

What to expect: Drinks and dinner buffet in the foyers of the conference venue.

Ticket: Everyone with a name badge is welcome.

Dress code: Smart casual

Conference Dinner

> An email with all details was sent to all participants who purchased a ticket.
In case of questions, please contact the registration desk.

Friday, November 13, 2026

19:30 – 23:00
(doors open 19:15, dinner starts 20:00)

Ticket: This event is sold out.

Please bring your name badge, as it includes a marker, serving as proof of eligibility for entry.

Dress code: Evening attire

Networking Event for Young Investigators

> An email with all details was sent to all participants who purchased a ticket.
In case of questions, please contact the registration desk.

Saturday, November 14, 2026

19:00 – 21:00

Ticket: This event is sold out.


Please bring your name badge, as it includes a marker, serving as proof of eligibility for entry.

Dress code: Smart casual

Keynote Talks

Keynote 1: **From Neural Crest to Schwann Cell Lineage**

Thursday, November 12, 2026 | Lecture Hall 1 + 2 (combined)
12:10-12:40



Igor Adameyko

Currently, Dr. Igor Adameyko is a Professor and a Department Chair at Center for Brain Research of Medical University of Vienna, Austria. He is known for the discovery of multipotency of nerve-associated Schwann cell precursors, a population of neural crest derived cells with exceptional plasticity and distribution in the body. Most lately, Prof. Adameyko engaged into the fields of neuroimmunology and onconeuroimmunology to discover how we can take advantage of altered cell states and cell-cell interactions for coping with a plethora of major human diseases.

Summary of the Talk

The Schwann cell lineage originates from multipotent neural crest cells, which play an essential role in establishing the vertebrate embryonic body plan. As neural crest cells migrate and associate with developing peripheral nerves, they give rise to Schwann cell precursors — a distinct population of nerve-associated multipotent progenitors capable of generating not only peripheral glia but also neurons, melanocytes, neuroendocrine cells, and mesenchymal derivatives. Schwann cell precursors that are not recruited into these alternative lineages progressively undergo fate restriction and differentiate into diverse peripheral glial populations, including myelinating, non-myelinating, terminal, and sensory Schwann cells. In my talk, I will discuss how the developmental potential of neural crest cells and Schwann cell precursors becomes progressively restricted, and how this process shapes the remarkable diversity of peripheral glial cell types.

Keynote 2: **Evidence to Action: How Advocacy Works Best**

Friday, November 13, 2026 | Lecture Hall 1 + 2 (combined)
09:50-10:20



Rachel Giles

Dr Rachel Giles comes from a family with NF1. Although she is originally from California, she has lived in the Netherlands for 35 years and pursued a career in hereditary cancer syndromes, specialising in von Hippel Lindau disease. A 3-time cancer survivor herself, she made a career switch in 2019, moving from her Associate Professor of Internal Medicine position at the University of Utrecht in the Netherlands to become a global patient advocate, running the International Kidney Cancer Coalition for 14 years. In 2025 she joined Patvocates, a social think tank active in health policy, as Patient Engagement Director.

Summary of the Talk

Patient advocacy is most effective when it is grounded in evidence rather than personal testimony alone. Drawing on her dual experience as a clinical scientist and a long-standing leader in the rare tumour syndrome community, she shows how patient organisations can generate and use data such as registries, surveys and patient-reported outcomes to strengthen their case. Evidence only creates change when it is translated into a clear, shared language that clinicians, researchers, regulators and industry can act on. Practical examples show how structured partnerships, including with pharmaceutical companies and European Reference Networks, can turn patient insights into better guidelines, research priorities and access to care. The neurofibromatosis community needs a call to action to involve patients partners in research and policy, and to build the evidence base needed for collective action.

Keynote 3: **Organoids**

Saturday, November 14, 2026 | Lecture Hall 1 + 2 (combined)
08:00-08:45



Arianna Baggiolini

Arianna Baggiolini's work lies at the intersection of stem cell biology and cancer. Since opening her laboratory in 2022, she has received the Christopher J. Marshall Award, the SNSF Starting Grant, the prestigious Hofschneider Professorship, the Young Investigator Award from the Horten Foundation and the 40 Under 40 in Cancer award. Her major contributions include defining oncogenic competence in melanoma and elucidating the role of developmental chromatin factors during tumor initiation and cellular maturation. Her research focuses on the mechanisms of competence for transformation and how cancer cells interact with the tumor microenvironment, particularly in tumor–neuron crosstalk.

HUMAN PLURIPOTENT STEM CELL-BASED MODELS OF HUMAN DEVELOPMENT AND DISEASE

Summary of the Talk

Advances in human pluripotent stem cell (hPSC) technologies now make it possible to derive virtually any cell type of the human body, as well as organ-specific organoids. This has opened the study of human cell types that were previously inaccessible for technical or ethical reasons. Neurons of both the central and peripheral nervous systems are a prime example: for the first time, we can study human neurons directly in the context of brain development and disease. In this talk, I will present our work using hPSC-derived brain organoids to investigate how the brain microenvironment shapes human neurodevelopment. Finally, I will introduce the new 3D models we are developing to study neuron–Schwann cell cross-talk.

Conference Programme Overview

You can also check the online programme here:

	Lecture Hall 1	Lecture Hall 2
Thursday, 12 November 2026		
12:00-12:10	**Welcome** *Claas Röhl, Amedeo Azizi*	
12:10-12:40	**Keynote 1:** From Neural Crest to Schwann Cell Lineage *Katharina Wimmer, Piotr Topilko, **Keynote Speaker: Igor Adameyko***	
12:40-14:30	**Plenary 1:** Genetic Aspects of Neurofibromatosis Type 1, Schwannomatosis and Related Disorders *Magdalena Koczkowska, Eric Legius, Priya Sharma, Katharina Wimmer*	
14:30-15:00	Coffee Break / Posters / Exhibition	
15:00-16:30	**Clinical Session 1:** Neuropsychosocial Implications *Ulrike Leiss, Andre Rietman, Andreu Coy*	**Basic Session 1:** Preclinical Models for Neurofibromatosis Type 1 and Schwannomatosis Pathogenesis *Piotr Topilko, Eduard Serra Arenas*
16:30-16:45	Coffee Break / Posters / Exhibition	
16:45-18:15	**Clinical Session 2:** Bone & Orthopedic Complications *Céline Colnot, Christof Radler, Iwo Koryciński*	**Basic Session 2:** Basic Biology underlying Neurofibromatosis Type 1 and Schwannomatosis *Anna Sablina, Santiago Vernia*
18:30-21:00	**Welcome Reception and Poster Area**	

Friday, 13 November 2026

	Lecture Hall 1	Lecture Hall 2
07:00-08:00		The Great NF / SWN Challenge: Pearls, Pitfalls and Prizes! – For Early Birds and Wise Owls! *Rosalie Ferner, Amedeo Azizi*
08:00-09:30	**Clinical Session 3:** Visible Manifestations in Neurofibromatosis *Laura Fertitta, Pierre Wolkenstein, Kimberly McCoy*	**Basic Session 3:** Basic and Translational Research in Schwannomatosis: Selected from Abstracts *Miriam Smith, Helen Morrisson, Priya Sharma*
09:30-09:50	Coffee Break / Posters / Exhibition	
09:50-10:20	**Keynote 2:** Evidence to Action – How Advocacy Works Best *Claas Röhl, Keynote Speaker: Rachel Giles*	
10:20-12:00	**Plenary 2:** Together – Patient Involvement in Research and Clinic *Claas Röhl, Rachel Giles*	
12:05-13:05	**Industry Session**	
13:10-14:25	**Plenary 3 - Part 1:** Pexiform Neurofibroma *Amedeo Azizi, Said Farschtschi, Catena Kresbach, Daan Van Dorp*	
14:25-14:50	Coffee Break / Posters / Exhibition	
14:50-16:10	**Plenary 3 - Part 2:** Malignant Progression from Neurofibroma to MPNST *Said Farschtschi, Catena Kresbach, Daan Van Dorp*	
16:10-16:30	Coffee Break / Posters / Exhibition	
16:30-18:00	**Clinical Session 4:** SWN Basket Session (Pain, Hybrid Tumors, etc.) *Said Chosro Farschtschi, Gareth Evans, Gilles Atlan*	**Basic Session 4:** Basic and Translational Research in Neurofibromatosis Type 1: Selected from Abstracts *Hilde Brems, Eva Trevission, Herb Sarnoff*
19:30-23:00	**Conference Dinner**	

Saturday, 14 November 2026

	Lecture Hall 1	Lecture Hall 2
08:00-08:45	**Keynote 3:** Organoids *Eduard Serra Arenas, Christian Oberdanner, Keynote Speaker: Arianna Baggiolini*	
08:45-10:10	**Plenary 4:** CNS Tumours in Neurofibromatosis Type 1 and Schwannomatosis *Enrico Opocher, Claas Röhl, Michel Kalamarides*	
10:10-10:30	Coffee Break / Posters / Exhibition	
10:30-11:50	**Clinical Session 5:** Imaging in Neurofibromatosis / SWN *Gregor Kasprian, Lennart Well*	**Basic Session 5:** Genomics and Bioinformatics for Neurofibromatosis Type 1 and Schwannomatosis *Bernhard Robl, Bernat Gel Moreno, Christian Oberdanner*
12:00-13:00	**Industry Session**	**Industry Session** (Transmission from Lecture Hall 1)
13:00-14:00	**Clinical Session 6:** Rare Manifestations *Eric Legius, Rianne Oostenbrink, Rachel Giles*	**Basic Session 6:** AI and Big Data in Neurofibromatosis Type 1 and Schwannomatosis Research *Bernhard Robl, Bernat Gel Moreno*
14:00-14:20	Coffee Break / Posters / Exhibition	
14:20-14:50	**Best Poster Awards & Lifetime Achievement Award** *Amedeo Azizi, Claas Röhl, Eduard Serra Arenas*	
14:50-15:30	**Theodor Schwann Awards** and Talk by Awardees *Laura Fertitta, Rianne Oostenbrink*	
15:30-16:30	**Plenary 5 - Part 1:** New Therapeutic Developments – Future Clinical Trials and Clinical Trial Design – Preclinical Drug Development *Amedeo Azizi, Johannes Gojo, Scott Plotkin, Claas Röhl*	
16:30-16:45	Coffee Break / Posters / Exhibition	
16:45-18:00	**Plenary 5 - Part 2:** New Therapeutic Developments – Future Clinical Trials and Clinical Trial Design – Preclinical Drug Development *Amedeo Azizi, Johannes Gojo, Scott Plotkin, Claas Röhl*	
18:00-18:15	Meeting Closure/ Farewell *Claas Röhl, Amedeo Azizi*	

Presentations Overview

Thursday, 12 November

12:00-12:10		**WELCOME,** Lecture Hall 1 + 2
12:00-12:10	OP001	WELCOME WORDS FROM AMEDEO AZIZI
12:00-12:10	OP002	WELCOME WORDS FROM CLAAS RÖHL
12:10-12:40		**Keynote 1: From Neural Crest to Schwann Cell Lineage,** Lecture Hall 1 + 2 *Chairs: Katharina Wimmer, Piotr Topilko*
12:10-12:40 25 minutes talk + 5 minutes Q&A	OP003	FROM NEURAL CREST TO SCHWANN CELL LINEAGE Igor Adameyko
12:40-14:30		**Plenary 1: Genetic Aspects of Neurofibromatosis Type 1, Schwannomatosis and Related Disorders,** Lecture Hall 1 + 2 *Chairs: Katharina Wimmer, Magdalena Koczkowska, Eric Legius, Priya Sharma*
12:40-12:52 12 minutes talk	OP004	NOVEL DEVELOPMENTS IN THE DIAGNOSTICS OF NEUROFIBROMATOSIS TYPE 1 AND RELATED DISORDERS Katharina Wimmer
12:52-13:04 12 minutes talk	OP005	MOSAICISM IN SCHWANNOMATOSIS: THE CHALLENGE OF MOLECULAR DETECTION Magdalena Koczkowska
13:04 13:19 15 minutes talk	OP006	ADVANCING VARIANT INTERPRETATION IN NEUROFIBROMATOSIS AND SCHWANNOMATOSIS: UPDATES FROM THE CLINGEN NF-SWN VARIANT CURATION EXPERT PANEL (VCEP) Elisabeth Castellanos Perez
13:29-13:39 17 minutes talk + 6 minutes Q&A of all previous speakers	OP007	REVEREND BAYES, CAFÉ-AU LAIT MACULES AND ACMG CLASSIFICATION GUIDELINES FOR GENETIC VARIANT INTERPRETATION Eric Legius
14:42-14:52 10 minutes talk + 2 minutes Q&A	OP008	CLINICAL AND MUTATIONAL SPECTRUM OF PIGMENTARY LESIONS ASSOCIATED WITH LZTR1: IMPLICATIONS IN NF1 DIAGNOSIS Laurence Pacot
13:54-14:04 10 minutes talk + 2 minutes Q&A	OP009	PACBIO TARGETED LONG-READ PANEL SEQUENCING: READY FOR IMPLEMENTATION AS THE PRINCIPAL ASSAY IN NF1 ROUTINE DIAGNOSTICS? Kimia Hashemi
14:06-14:16 10 minutes talk + 2 minutes Q&A	OP010	DEEP SEQUENCING DETECTS LOW-LEVEL MOSAIC VARIANTS IN SUSPECTED NEUROFIBROMATOSIS TYPE 1 AND SCHWANNOMATOSIS PATIENTS Rick Van Minkelen
14:18-14:28 10 minutes talk + 2 minutes Q&A	OP011	ERBB2 MOSAICISM IN PATIENTS WITH MULTIPLE BENIGN PERIPHERAL NERVE SHEATH TUMORS Yvette van Ierland

15:00-16:30	**Clinical Session 1: Neuropsychosocial Implications**, Lecture Hall 1 *Chairs: Ulrike Leiss, Andre Rietman, Andreu Coy*
15:00-15:17 OP012 17 minutes talk + 3 minutes Q&A	LIVING WITH NF1 BEYOND TUMOUR BURDEN AND SOMATIC COMPLICATIONS Andre Rietman
15:20-15:34 OP013 14 minutes talk + 3 minutes Q&A	LIVED EXPERIENCES ON SEXUALITY IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1: A QUALITATIVE STUDY Sarah Van Dijk
15:37-15:51 OP014 14 minutes talk + 3 minutes Q&A	PSYCHOMETRIC ANALYSIS OF THE PAIN INTERFERENCE INDEX FOR PLEXIFORM NEUROFIBROMAS IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS BASED ON KOMET STUDY DATA Ayo Adeyemi
15:54-16:08 OP015 14 minutes talk + 3 minutes Q&A	INTEGRATING THE SOCIAL DIMENSION INTO PEDIATRIC NEUROFIBROMATOSIS CARE: A PILOT STUDY OF FAMILY NEEDS Kerstin Krottendorfer
16:11-16:25 OP016 14 minutes talk + 3 minutes Q&A	COGNITIVE FUNCTION IN ADULT NF1 PATIENTS WITHOUT OTHER COGNITIVE DISORDERS: A CROSS-SECTIONAL STUDY Daniel Muñoz Pérez

15:00-16:30	**Basic Session 1: Preclinical Models for Neurofibromatosis Type 1 and Schwannomatosis Pathogenesis,** Lecture Hall 2 *Chairs: Piotr Topilko, Eduard Serra Arenas*
15:00-15:20 OP017 20 minutes talk + 5 minutes Q&A	PRECLINICAL MODELS: TIPS & TRICK AND BEYOND Piotr Topilko
15:26-15:36 OP018 10 minutes talk + 5 minutes Q&A	GENERATION OF DIFFERENT iPSC-DERIVED NEURAL CREST-BASED MODELS OF NF1 MPNSTs CARRYING DISTINCT TUMOR SUPPRESSOR GENE INACTIVATION SIGNATURES Judit Farrés
15:42-15:52 OP019 10 minutes talk + 5 minutes Q&A	CONDITIONAL Nf2 INACTIVATION IN Foxj1 EPENDYMAL CELLS INDUCES EPENDYMAL PROLIFERATION AND CYSTIC DILATIONS Michel Kalamarides
15:58-16:08 OP020 10 minutes talk + 5 minutes Q&A	EXPLORING THE ROLE OF THE HUMAN MICROENVIRONMENT IN NEUROFIBROMATOSIS USING HUMAN PLURIPOTENT STEM CELLS Jonas Van Lent
16:14-16:24 OP021 10 minutes talk + 5 minutes Q&A	INVESTIGATING THE NEURODEVELOPMENTAL DEFICITS IN LEGIUS SYNDROME USING PATIENT-DERIVED IPSCS Seppe Van der Auweraer

16:45-18:15		**Clinical Session 2 (Joint with Basic Science) - Bone and Orthopaedic Aspects of NF1**, Lecture Hall 1 *Chairs: Céline Colnot, Christof Radler, Iwo Korycinski*
16:45-17:00 15 minutes talk + 5 minutes Q&A	OP022	PATHOGENIC MECHANISMS OF BONE MANIFESTATIONS IN NEUROFIBROMATOSIS TYPE 1 Céline Colnot
17:05-17:20 15 minutes talk + 5 minutes Q&A	OP023	TREATMENT OF CONGENITAL PSEUDARTHROSIS OF THE TIBIA (CPT) Christof Radler
17:25-17:34 9 minutes talk + 3 minutes Q&A	OP024	SKELETAL ABNORMALITIES IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1: A CROSS-SECTIONAL STUDY Xuan Yu
17:37-17:46 9 minutes talk + 3 minutes Q&A	OP025	QUANTITATIVE ULTRASOUND IMAGING AS A POTENTIAL SCREENING TOOL FOR CONGENITAL TIBIAL DYSPLASIA IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 Alicia Baumgartner
17:49-17:58 9 minutes talk + 3 minutes Q&A	OP026	LONGITUDINAL EVALUATION OF BONE MINERAL DENSITY IN CHILDREN AND YOUNG ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) RECEIVING SELUMETINIB ON THE NCI SPRINT TRIAL Eva Dombi
18:01-18:10 9 minutes talk + 3 minutes Q&A	OP028	SELLA TURCICA MEASUREMENTS IN NF1 Reinhard E. Friedrich

16:45-18:15		**Basic Session 2: Basic Biology underlying Neurofibromatosis Type 1 and Schwannomatosis**, Lecture Hall 2 *Chairs: Santiago Vernia, Anna Sablina*
16:45-17:00 15 minutes talk + 5 minutes Q&A	OP029	RAS SIGNALING IN NF1 AND SCHWANNOMATOSIS: MOLECULAR MECHANISMS AND THERAPEUTIC OPPORTUNITIES Anna Sablina
17:05-17:18 13 minutes talk + 3 minutes Q&A	OP030	FUNCTIONAL CHARACTERISATION OF A NOVEL NF2-DEFICIENT MACROPHAGE CELL LINE REVEALS PRESERVED INFLAMMATORY AND PHAGOCYTIC RESPONSES Abigail Owen
17:22-17:35 13 minutes talk + 3 minutes Q&A	OP031	MOLECULAR AND IMMUNOHISTOCHEMICAL COMPARISON OF PRIMARY AND RECURRENT MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST) Greta Klohk
17:39-17:52 13 minutes talk + 3 minutes Q&A	OP032	GAP, MAP OR BOTH? A NOVEL, RAS-INDEPENDENT FUNCTION FOR Nf1 IN MICROTUBULAR DYNAMICS Luca Mazzarella
17:55-18:15 15 minutes talk + 5 minutes Q&A	OP034	RNA-BASED APPROACHES IN NEUROFIBROMATOSIS TYPE 1 Santiago Vernia

Friday, 13 November

07:00-08:00		**The Great NF / SWN Challenge: Pearls, Pitfalls and Prizes! - For Early Birds and Wise Owls!** Lecture Hall 2 *Chairs: Rosalie Ferner, Amedeo Azizi, Priya Sharma*
07:00-8:00	OP035	THE GREAT NF / SWN CHALLENGE: PEARLS, PITFALLS AND PRIZES! Rosalie Ferner
07:00-8:00	OP036	THE GREAT NF / SWN CHALLENGE: PEARLS, PITFALLS AND PRIZES! Amedeo Azizi
08:00-09:30		**Clinical Session 3: Visible Manifestations in Neurofibromatosis,** Lecture Hall 1 *Chairs: Laura Fertitta, Pierre Wolkenstein, Kimberley McCoy*
08:00-08:10 10 minutes talk + 3 minutes Q&A	OP037	ENDING CUTANEOUS NEUROFIBROMA Pierre Wolkenstein
08:13-08:23 10 minutes talk + 3 minutes Q&A	OP038	MORE THAN SKIN DEEP: WHAT VISIBLE NF1 MEANS FOR PATIENTS Kimberley McCoy
08:26-08:36 10 minutes talk + 3 minutes Q&A	OP039	EVIDENCE-BASED CONSENSUS-DRIVEN ASSESSMENT OF OUTCOME MEASURES FOR CUTANEOUS NEUROFIBROMAS IN Nf1 Laura Fertitta
08:39-08:49 10 minutes talk + 3 minutes Q&A	OP040	A PHASE 1/1b OPEN LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PAS-004, A MACROCYCLIC MEK INHIBITOR, IN ADULT PARTICIPANTS WITH NF1-ASSOCIATED CUTANEOUS NEUROFIBROMA (cNF) Rebecca Brown
08:52-09:02 10 minutes talk + 3 minutes Q&A	OP041	A 16 YEAR COST EVALUATION OF ELECTRODESSICATION OF CUTANEOUS NEUROFIBROMATA COMPARED TO EXCISION OF SYMPTOMATIC LESIONS ALONE Anna Payne
09:05-09:15 10 minutes talk + 3 minutes Q&A	OP042	BEYOND CAFÉ-AU-LAIT SPOTS: REAL-WORLD BURDEN OF PLEXIFORM NEUROFIBROMAS, OPTIC GLIOMAS, NEURODEVELOPMENTAL IMPAIRMENT, AND CHRONIC PAIN IN A NATIONAL NEUROFIBROMATOSIS TYPE 1 REGISTRY OF 4,230 PATIENTS Peter Vasiluev
09:18-09:28 10 minutes talk + 3 minutes Q&A	OP043	OUTCOMES AND COST EVALUATION OF THE USE OF PRE-OPERATIVE EMBOLIZATION IN PATIENTS WITH PLEXIFORM NEUROFIBROMAS Lucy Homer Newton

08:00-09:30		**Basic Session 3: Basic and Translational Research in Schwannomatosis: Selected from Abstracts**, Lecture Hall 2 *Chairs: Miriam Smith, Helen Morrisson, Priya Sharma*
08:00-08:12 12 minutes talk + 3 minutes Q&A	OP045	GENOTYPE-PHENOTYPE CORRELATIONS IN CHILDHOOD NF2-RELATED SCHWANNOMATOSIS USING THE NF2 GENETIC SEVERITY SCORE Jack Read
08:15-08:27 12 minutes talk + 3 minutes Q&A	OP046	IDENTIFYING HIGH RISK STRUCTURAL VARIANTS IN NF2-ASSOCIATED TUMORS Haley Atkins
08:30-08:42 12 minutes talk + 3 minutes Q&A	OP047	PHENOTYPIC EVALUATION OF INDIVIDUALS WITH RING CHROMOSOME 22 ASCERTAINED THROUGH NATIONAL NF2-RELATED SCHWANNOMATOSIS SERVICES Miranda Rogers
08:45-08:57 12 minutes talk + 3 minutes Q&A	OP048	A NOVEL COMBINATION STRATEGY TARGETING MITOTIC REGULATION AND MEK IN NF2-DEFICIENT SCHWANN CELLS Cixin Huang
09:00-09:12 12 minutes talk + 3 minutes Q&A	OP049	SCHWANN CELL-SPECIFIC LOSS OF LZTR1 IMPAIRS LIPID METABOLISM AND ACTIVATES ERK SIGNALING DRIVING NEUROPATHIC PAIN AND NERVE HYPERTROPHY Georgia Daraki
09:15-09:27 12 minutes talk + 3 minutes Q&A	OP050	PATIENT-DERIVED VESTIBULAR SCHWANNOMA ORGANOIDS: A THREE-DIMENSIONAL EX VIVO MODEL FOR LONG-TERM CULTURE AND DRUG TESTING Eva Meller
09:50-10:20		**Keynote 2: Evidence to Action: How Advocacy Works Best**, Lecture Hall 1 + 2 *Chairs: Rachel Giles, Claas Röhl*
09:50-10:20 25 minutes talk + 5 minutes Q&A	OP051	EVIDENCE TO ACTION: HOW ADVOCACY WORKS BEST Rachel Giles
10:20-12:00		**Plenary 2: Together - Patient Involvement in Research and Clinic**, Lecture Hall 1 + 2 *Chairs: Rachel Giles, Claas Röhl*
10:20-10:30 10 minutes talk + 3 minutes Q&A	OP052	PATIENT REPORTED OUTCOMES RESEARCH IN NF BY THE REINS COLLABORATION Vanessa L. Merker
10:33-10:43 10 minutes talk + 3 minutes Q&A	OP053a OP053b	COMMUNITY ADVISORY BOARD FOR NF1 Kimberley McCoy Iwo Korycinski
10:46-10:51 5 minutes talk + 2 minutes Q&A	OP054	A PAN-EUROPEAN STUDY ON THE PSYCHOSOCIAL BURDEN AND UNMET NEEDS OF PATIENTS WITH NF1 AND THEIR FAMILIES Vera Lipkovskaya

10:53-11:03 10 minutes talk + 3 minutes Q&A	OP055	CAPACITY BUILDING PROGRAMMES FOR PATIENT REPRESENTATIVES (NF ACADEMY, EURORDIS, EUPATI, WECAN...) Claas Röhl
11:06-11:14 8 minutes talk + 2 minutes Q&A	OP056	FAMILY PLANNING IN NEUROFIBROMATOSIS TYPE 1: COUPLES' PERSPECTIVES ON PREIMPLANTATION GENETIC TESTING AND OTHER REPRODUCTIVE OPTIONS Vivian Vernimmen
11:16-11:24 8 minutes talk + 2 minutes Q&A	OP057	IDENTIFYING TRANSITION NEEDS IN ADOLESCENTS AND YOUNG ADULTS WITH NEUROFIBROMATOSIS: FINDINGS FROM A PARTICIPATORY CO-CREATION STUDY Doris Hoffmann-Lamplmair
11:26-12:00 34 minutes talk + 2 minutes Q&A	OP058	PANEL DISCUSSION all Speakers
12:05-13:05	OP059	**Industry Session**, Lecture Hall 1 + 2
13:10-14:25		**Plenary 3 - Part 1: Pexiform Neurofibroma**, Lecture Hall 1 + 2 *Chairs: Catena Kresbach, Said Chosro Farschtschi, Daan van Dorp, Amedeo Azizi*
13:10-13:20 10 minutes talk + 2 minutes Q&A	OP060	INTRODUCTION Said Chosro Farschtschi
13:22-13:33 11 minutes talk + 4 minutes Q&A	OP061	LONG-TERM ANALYSIS OF MIRDAMETINIB TREATMENT IN ADULTS AND CHILDREN WITH SYMPTOMATIC NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN): UPDATED PHASE 2B RENEU TRIAL FINDINGS Dusica Babovic-Vuksanovic
13:37-13:47 10 minutes talk + 3 minutes Q&A	OP062	PLEXIFORM NEUROFIBROMA OF HEAD, NECK, AND FACIAL REGIONS: TOPOGRAPHXY OF LESIONS AND TREATMENT Reinhard E. Friedrich
13:50-14:00 10 minutes talk + 3 minutes Q&A	OP063	USE OF MIRDAMETINIB FOR THE TREATMENT OF NEUROFIBROMATOSIS TYPE 1–ASSOCIATED PLEXIFORM NEUROFIBROMAS (NF1-PN) IN PATIENTS WITH PRIOR MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) KINASE INHIBITOR (MEKI) EXPOSURE Andrea T. Franson
14:03-14:12 9 minutes talk + 2 minutes Q&A	OP064	REAL-WORLD USE OF MEDICATIONS WITH MODERATE-TO-STRONG CYTOCHROME P450 3A4 (CYP3A4) INDUCTION/INHIBITION OR POTENTIAL TO INCREASE THE RISK FOR BLEEDING IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN): A UNITED STATES (US) CLAIMS DATABASE ANALYSIS Abraham Langseth
14:14-14:23 9 minutes talk + 2 minutes Q&A	OP065	EFFECTIVENESS OF SELUMETINIB IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1 AND SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS: AN ITALIAN REAL-LIFE EXPERIENCE Antonella Cacchione

14:50-16:10		**Plenary 3 - Part 2: Malignant Progression from Neurofibroma to MPNST**, Lecture Hall 1 + 2 *Chairs: Catena Kresbach, Said Chosro Farschtschi, Daan van Dorp*
14:50-15:05 15 minutes talk + 5 minutes Q&A	OP066	FROM NEUROFIBROMA TO MPNST: MOLECULAR PATHWAYS AND DIAGNOSTIC CHALLENGES Catena Kresbach
15:10-15:25 15 minutes talk + 3 minutes Q&A	OP067	MAPPING THE CELLULAR EVOLUTION AND HETEROGENEOUS STATES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS Jagjot Arora
15:28-15:43 15 minutes talk + 3 minutes Q&A	OP068	ACCELERATING BIOMARKER RESEARCH IN NEUROFIBROMATOSIS TYPE 1: THE NF1 NETHERLANDS NETWORK REGISTRY AND BIOBANK (NF1-NNRB) Lara Orlandini
15:46-15:56 10 minutes talk + 2 minutes Q&A	OP069	NERVE FUNCTION PRESERVATION VERSUS RADICAL RESECTION IN BORDERLINE NEUROFIBROMATOUS LESIONS Simon Miedema
16:58-16:08 10 minutes talk + 2 minutes Q&A	OP070	A DECADE OF EXPERIENCE MANAGING ATYPICAL NEUROFIBROMATOUS NEOPLASMS OF UNCERTAIN BIOLOGIC POTENTIAL (ANNUBP) IN A TERTIARY NEUROFIBROMATOSIS SERVICE Lucy Homer Newton
16:30-18:00		**Clinical Session 4: SWN Basket Session (Pain, Hybrid Tumours, etc.)**, Lecture Hall 1 *Chairs: Gareth Evans, Said Chosro Farschtschi, Gilles Atlan*
16:30-16:45 15 minutes talk + 5 minutes Q&A	OP071	INHERITED GENETICS OF SCHWANNOMATOSIS Gareth Evans
16:50-17:04 14 minutes talk + 3 minutes Q&A	OP072	PAIN TRAJECTORY IN NON-NF2-RELATED SCHWANNOMATOSIS: A PROSPECTIVE, INTERNATIONAL, MULTICENTER, OBSERVATIONAL STUDY Scott R. Plotkin
17:08-17:21 14 minutes talk + 3 minutes Q&A	OP073	NF2-RELATED SCHWANNOMATOSIS IN CHILDREN: A NATIONAL COHORT OF 275 PATIENTS Jack Read
17:25-17:39 14 minutes talk + 3 minutes Q&A	OP074	DEVELOPMENT AND INITIAL VALIDATION OF THE QUALITY OF LIFE EVALUATION IN NF2-RELATED SCHWANNOMATOSIS TRIALS (QUEST) ASSESSMENT Vanessa L. Merker
17:43-17:57 14 minutes talk + 3 minutes Q&A	OP075	AUDITORY BRAINSTEM IMPLANTATION: A SINGLE-CENTER EXPERIENCE Erdem Yildiz

16:30-18:00		**Basic Session 4: Basic and Translational Research in Neurofibromatosis Type 1: Selected from Abstracts**, Lecture Hall 2 *Chairs: Hilde Brems, Eva Trevisson, Herb Sarnoff*
16:30-16:50 15 minutes talk + 5 minutes Q&A	OP076	GENE THERAPY TO TREAT NEUROFIBROMATOSIS USING A FOAMY VIRAL VECTOR David Deyle
16:55-17:10 15 minutes talk + 5 minutes Q&A	OP077	LOCOREGIONAL INTRAVASCULAR DELIVERY OF LIPID NANOPARTICLES ENHANCES TARGETED GENE EXPRESSION TOWARD GENE REPLACEMENT THERAPY FOR NEUROFIBROMATOSIS TYPE 1 Gonzalo Fernández-Miranda
17:15-17:30 15 minutes talk + 5 minutes Q&A	OP078	STIMULATION OF NEUROFIBROMIN PRODUCTION BY CRISPR-dCAS-VP64 OR THE RE-PURPOSING OF DRUGS: THERAPEUTIC OPPORTUNITIES FOR NEUROFIBROMATOSIS TYPE1 Erik Wiemer
17:35-17:50 15 minutes talk + 5 minutes Q&A	OP079	HEXOKINASE 2 DISPLACEMENT FROM MITOCHONDRIA-ASSOCIATED MEMBRANES AS A NOVEL TREATING STRATEGY FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS Andrea Rasola

Saturday, 14 November

08:00-08:45 **Keynote 3: Organoids**, Lecture Hall 1 + 2
Chairs: Arianna Baggiolini, Eduard Serra Arenas, Christian Oberdanner

08:00-08:45 OP080
40 minutes talk + 5 minutes Q&A
HUMAN PLURIPOTENT STEM CELL-BASED MODELS OF HUMAN DEVELOPMENT AND DISEASE
Arianna Baggiolini

08:45-10:10 **Plenary 4: CNS Tumours in Neurofibromatosis Type 1 and Schwannomatosis**, Lecture Hall 1 + 2
Chairs: Enrico Opocher, Michael Kalamarides, Claas Röhl

08:45-08:56 OP081
11 minutes talk + 2 minutes Q&A
NF1-ASSOCIATED OPG AND VISUAL-RELATED OUTCOMES
Enrico Opocher

08:58-09:08 OP082
10 minutes talk + 2 minutes Q&A
NF1 OPTIC PATHWAY GLIOMA IDENTIFIED BY MRI SCREENING - A SINGLE CENTRE EXPERIENCE
Abed Ahmadi

09:10-09:20 OP083
10 minutes talk + 2 minutes Q&A
PILOCYTIC ASTROCYTOMA ARISING IN NEUROFIBROMATOSIS TYPE 1 ARE A DISTINCT MOLECULAR ENTITY
Lara Orlandini

09:22-09:32 OP084
10 minutes talk + 2 minutes Q&A
CLINICAL FEATURES AND PROGNOSTIC INDICATORS IN ADULTS WITH BIOPSY-PROVEN NEUROFIBROMATOSIS TYPE 1-ASSOCIATED LOW-GRADE GLIOMA
Chelsea Kotch

09:34-09:44 OP085
10 minutes talk + 2 minutes Q&A
PREDICTING TUMOUR ONSET AND SURVIVAL IN CHILDHOOD NF2-RELATED SCHWANNOMATOSIS
Jack Read

09:46-09:56 OP086
10 minutes talk + 2 minutes Q&A
CLINICAL, PATHOLOGICAL AND GENETIC DETERMINANTS OF RECURRENCE IN NF2-ASSOCIATED MENINGIOMAS: A RETROSPECTIVE SINGLE-CENTRE STUDY
Jack Sheppard

09:58-10:08 OP087
10 minutes talk + 2 minutes Q&A
BEVACIZUMAB TREATMENT IN NF2-SCHWANNOMATOSIS: A LONG TERM SINGLE INSTITUTION EXPERIENCE
Marica Eoli

10:30-11:50 **Clinical Session 5: Imaging in Neurofibromatosis / SWN**, Lecture Hall 1
Chairs: Gregor Kasprian, Lennart Well, Riccardo Buttarelli

10:30-10:45 OP088
15 minutes talk + 2 minutes Q&A
IMAGING IN NEUROFIBROMATOSIS: RADIOLOGICAL CHALLENGES IN THE ERA OF AI
Lennart Well

10:47-10:54 OP089
7 minutes talk + 2 minutes Q&A
RADIOLOGY IMAGING-INITIATED MOLECULAR SUBTYPING AND UNDERLYING MECHANISM EXPLORING OF RARE DISEASES: A MULTI-CENTER STUDY
Cheng-Jiang Wei

10:56-11:03 7 minutes talk + 2 minutes Q&A	OP090	AI-ASSISTED IMAGING MODELS FOR NF1-PNF MANAGEMENT Jun Liu
11:05-11:12 7 minutes talk + 2 minutes Q&A	OP091	LONGITUDINAL VOLUMETRIC ANALYSIS OF NF1 OPTIC PATHWAY GLIOMAS USING A WEB-BASED AI TOOL: CAVS-NF1 Robert Avery
11:14-11:21 7 minutes talk + 2 minutes Q&A	OP092	MRI RESPONSE ASSESSMENT IN NF1-PN TREATMENT: BRIDGING TRIAL STANDARDS AND CLINICAL PRACTICE Lara Orlandini
11:23-11:30 7 minutes talk + 2 minutes Q&A	OP093	INTEGRATING MRI RADIOMICS AND OCT TO IMPROVE PREDICTION OF VISUAL DETERIORATION IN NF1-ASSOCIATED OPTIC PATHWAY GLIOMAS Gianluca Piccolo
11:32-11:39 7 minutes talk + 2 minutes Q&A	OP094	THE SPECTRUM OF HYDROCEPHALUS AND UNDERLYING PATHOPHYSIOLOGICAL PROCESSES IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 Wisal Al Sukaiti
11:41-11:48 7 minutes talk + 2 minutes Q&A	OP095	THE ROLE OF 18F-FDG-PET/CT IN IDENTIFYING MALIGNANT TRANSFORMATION OF NEUROFIBROMAS IN PATIENTS WITH NF1 REFERRED TO THE NHS ENGLAND HIGHLY SPECIALISED SERVICE IN MANCHESTER Jawad Naqvi

10:30-11:50	**Basic Session 5: Genomics and Bioinformatics for Neurofibromatosis Type 1 and Schwannomatosis**, Lecture Hall 2 *Chairs: Bernhard Robl, Bernat Gel Moreno, Christian Oberdanner*

10:30-10:45 15 minutes talk + 5 minutes Q&A	OP096	GENOMICS OF MPNST: FINDINGS, DATA AND OPPORTUNITIES Bernat Gel Moreno
10:50-11:02 12 minutes talk + 3 minutes Q&A	OP097	ASSOCIATIONS BETWEEN NF1 GENOTYPE AND CLINICAL PHENOTYPES IN NEUROFIBROMATOSIS TYPE 1: A RETROSPECTIVE COHORT STUDY Zhichao Wang
11:05-11:17 12 minutes talk + 3 minutes Q&A	OP098	METHYLATION PROFILING DEFINES TWO BIOLOGICALLY DISTINCT SUBGROUPS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOURS WITH DIVERGENT CLINICAL OUTCOMES, TUMOUR MICROENVIRONMENT, AND RESPONSE TO SURGICAL RESECTION Chloe Gui
11:20-11:32 12 minutes talk + 3 minutes Q&A	OP099	BEYOND PRC2 INACTIVATION: IDENTIFICATION OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR SUBTYPES WITH DISTINCT GENOMIC IDENTITIES IN NF1 PATIENTS Miriam Magallón-Lorenz
11:35-11:47 12 minutes talk + 3 minutes Q&A	OP100	ONE-TWO PUNCH SENOGENIC AND SENOLYTIC STRATEGIES AGAINST PERIPHERAL NERVE SHEATH TUMORS Bernhard Robl

12:00-13:00	OP101	**Industry Session,** Lecture Hall 1 + Transmission in Lecture Hall 2

13:00-14:00		**Clinical Session 6: Rare / Miscellaneous Manifestations**, Lecture Hall 1 *Chairs: Eric Legius, Rianne Oostenbrink, Rachel Giles*
13:00-13:10 10 minutes talk + 2 minutes Q&A	OP102	RARE PHENOTYPES ASSOCIATED WITH NF1 Eric Legius
13:12-13:22 10 minutes talk + 2 minutes Q&A	OP103	GROWTH HORMONE TREATMENT IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 Joana Simões Pereira
13:24-13:34 10 minutes talk + 2 minutes Q&A	OP104	VASCULOPATHY AND ISCHEMIC INJURY RISK IN CHILDREN WITH NEUROFIBROMATOSIS TYPE I: A NATIONAL RETROSPECTIVE COHORT STUDY Stavros Stivaros
13:36-13:46 10 minutes talk + 2 minutes Q&A	OP105	NEUROFIBROMATOSIS TYPE 1-ASSOCIATED BREAST CANCER: CLINICAL PRESENTATION, TUMOR SUBTYPES, MOLECULAR SPECTRUM, AND FUNCTIONAL ANALYSIS Alessandro De Luca
13:48-13:58 10 minutes talk + 2 minutes Q&A	OP106	NEUROLOGICAL MORBIDITY IN NEUROFIBROMATOSIS 1: A NATIONWIDE, REGISTER-BASED COHORT STUDY Mette Møller Handrup

13:00-14:00		**Basic Session 6: AI and Big Data in Neurofibromatosis Type 1 and Schwannomatosis Research**, Lecture Hall 2 *Chairs: Bernhard Robl, Bernat Gel Moreno*
13:00-13:15 15 minutes talk + 5 minutes Q&A	OP108	cNF-VISION: LESION-LEVEL IMAGE ANALYSIS OF CUTANEOUS NEUROFIBROMAS IN A LARGE NEUROFIBROMATOSIS TYPE 1 COHORT Christoph Sadée
13:20-13:35 15 minutes talk + 5 minutes Q&A	OP109	CHALLENGES OF AI-ASSISTED NEUROFIBROMA ANALYSIS IN MRI Georgii Kolokolnikov
13:40-13:55 15 minutes talk + 5 minutes Q&A	OP110	RADIOGENOMICS IN NF2-ASSOCIATED SCHWANNOMATOSIS (NEUROFIBROMATOSIS TYPE II): EXPLORATORY DATA ANALYSIS Elizabeth Makashova

14:20-14:50		**Best Poster Awards & Livetime Achievement Award**, Lecture Hall 1+2 *Chairs: Amedeo Azizi, Claas Röhl, Eduard Serra Arenas*
14:20-14:22 2 minutes talk + 1 min handover + photo	OP111a	INTRODUCTION - BEST POSTER AWARD - BASIC SCIENCE Eduard Serra
14:23-14:25 2 minutes talk	OP111b	PRESENTATION AWARDEE - BEST POSTER AWARD - BASIC SCIENCE
14:25-14:27 2 minutes talk + 1 min handover + photo	OP112a	INTRODUCTION - BEST POSTER AWARD - CLINICAL SCIENCE Amedeo Azizi
14:28-14:30 2 minutes talk	OP112b	PRESENTATION AWARDEE - BEST POSTER AWARD - CLINICAL SCIENCE
14:30-14:50	OP113	LIFETIME ACHIEVEMENT AWARD Claas Röhl and Eric Legius

14:50-15:30		**Theodor Schwann Awards and Talks by Awardees**, Lecture Hall 1+2 *Chairs: Amedeo Azizi, Claas Röhl*
14:50-14:55 5 minutes talk	OP114	INTRODUCTION FIRST THEODOR SCHWANN AWARDEE
14:55-15:10 15 minutes talk	OP115	FIRST THEODOR SCHWANN AWARDEE TALK First Awardee
15:10-15:15 5 minutes talk	OP116	INTRODUCTION SECOND THEODOR SCHWANN AWARDEE
15:15-15:30 5 minutes talk + 3 minutes Q&A	OP117	SECOND THEODOR SCHWANN AWARDEE TALK Second Awardee
15:30		Photo

15:30-16:30		**Plenary 5: New Therapeutic Developments - Future Clinical Trials and Clinical Trial Design - Preclinical Drug Development – Part 1**, Lecture Hall 1+2 *Chairs: Amedeo Azizi, Claas Röhl, Johannes Gojo, Scott R. Plotkin*
15:30-15:45 15 minutes talk + 5 minutes Q&A	OP119	NOVEL PRECLINICAL MODELS TO ENABLE DISEASE-SPECIFIC TREATMENT FOR NEUROFIBROMATOSIS Johannes Gojo

15:50-15:58 8 minutes talk + 2 minutes Q&A	OP120	DESIGN AND METHODOLOGY OF EUROPEAN NF ATLAS. MAPPING CLINICAL CARE AND TRIAL READINESS IN NEUROFIBROMATOSIS AND SCHWANNOMATOSIS Dariusz Adamczewski
16:00-16:08 8 minutes talk + 2 minutes Q&A	OP121	PRE-CLINICAL EVALUATION OF A PAN-KRAS INHIBITOR ON CUTANEOUS NEUROFIBROMAS IN NEUROFIBROMATOSIS TYPE 1 MOUSE MODEL Laura Fertitta
16:10-16:18 8 minutes talk + 2 minutes Q&A	OP122	A PAEDIATRIC PHASE 1 STUDY OF INTERMITTENT DOSING OF THE MEK-1 INHIBITOR SELUMETINIB IN CHILDREN WITH NEUROFIBROMATOSIS TYPE-1 AND INOPERABLE PLEXIFORM NEUROFIBROMA Patricia O'Hare
16:20-16:28 8 minutes talk + 2 minutes Q&A	OP123	DUAL INHIBITION OF OXIDATIVE PHOSPHORYLATION AND THE MEVALONATE PATHWAY UNCOVERS A THERAPEUTIC VULNERABILITY IN NF1-ASSOCIATED NEUROFIBROMAS Eric Pasmant
16:45-18:00		**Plenary 5: New Therapeutic Developments - Future Clinical Trials and Clinical Trial Design - Preclinical Drug Development – Part 2**, Lecture Hall 1+2 *Chairs: Amedeo Azizi, Claas Röhl, Johannes Gojo, Scott R. Plotkin*
16:45-17:00 15 minutes talk + 4 minutes Q&A	OP124	RETHINKING CLINICAL TRIAL DESIGN FOR NEUROFIBROMATOSIS AND SCHWANNOMATOSIS Scott R. Plotkin
17:04-17:15 11 minutes talk + 3 minutes Q&A	OP125	iPSC-BASED MERLIN-DEFICIENT SCHWANN CELL-LIKE SPHEROIDS AS A NEW IN VITRO MODEL SYSTEM FOR EVALUATING NEW THERAPEUTIC APPROACHES Elisabeth Castellanos
17:18-17:29 11 minutes talk + 3 minutes Q&A	OP126	A SINGLE CENTRE CASE SERIES OF BRIGATINIB, A MULTI TYROSINE KINASE INHIBITOR IN NF2-SWN MENINGIOMAS Tim Lavin
17:32-17:43 11 minutes talk + 3 minutes Q&A	OP128	RE-RESPONSE TO SELUMETINIB AFTER PROLONGED TREATMENT INTERRUPTION ON CLINICAL TRIALS FOR NEUROFIBROMATOSIS TYPE 1 (NF1) PLEXIFORM NEUROFIBROMAS Eva Dombi
17:46-17:57 11 minutes talk + 3 minutes Q&A	OP129	FINAL RESULTS ON BRIGATINIB TREATMENT FOR PROGRESSIVE TUMORS IN PATIENTS WITH NF2-RELATED SCHWANNOMATOSIS: A SUB-STUDY OF THE INTUITT-NF2 TRIAL Scott R. Plotkin
18:00-18:15		**Meeting Closure / Farewell**, Lecture Hall 1+2
18:00-18:15	OP130	CLOSING WORDS Amedeo Azizi, Claas Röhl

List of Posters

During the conference, the following posters will be displayed in the Poster Area in the "Upper Belvedere" rooms. The posters are numbered with P1-P97 and are sorted by content. A detailed view of the content of the accepted abstracts can be found in the printed Abstract Book or online.

Poster Area

Posters related to **Plenary 1: Genetic Aspects of Neurofibromatosis Type 1, Schwannomatosis and Related Disorders**

P1 UNMASKING NF1 MOSAICISM: OPTICAL GENOME MAPPING IDENTIFIES A NOVEL T(15;17) TRANSLOCATION IN MELANOCYTES
Aude Beyens

P2 CLINICAL HETEROGENEITY AND MOLECULAR CHARACTERIZATION OF A LARGE COHORT OF PATIENTS WITH LEGIUS SYNDROME: A RETROSPECTIVE MULTICENTER STUDY
Roberta Palmitessa

P3 REFINING THE CLINICAL SPECTRUM OF MOSAIC NEUROFIBROMATOSIS TYPE 1
Laurence Pacot

P4 MOSAIC NEUROFIBROMATOSIS TYPE 1 CLINICAL MANIFESTATIONS AND NATURAL HISTORY - A MULTICENTER EXPERIENCE
Reeval Segel

P5 FAMILIAL NF2-SCHWANNOMATOSIS SOLVED BY LONG-READ SEQUENCING
Chiara Canciani

P6 GERMLINE AND SOMATIC NEUROFIBROMATOSIS TYPE 1 VARIANT LANDSCAPE ACROSS 4,230 PATIENTS: FINDINGS FROM ONE OF THE LARGEST NATIONAL REGISTRIES
Peter Vasiluev

P7 GENOTYPE–ENDOCRINE PHENOTYPE ASSOCIATIONS IN NEUROFIBROMATOSIS TYPE 1: A SINGLE-CENTER RETROSPECTIVE STUDY
Joana Simões Pereira

Posters related to **Clinical Session 1: Neuropsychosocial Implications**

P8 ADDRESSING THE PSYCHOSOCIAL NEEDS OF CHILDREN AND ADOLESCENTS WITH NEUROFIBROMATOSIS AND THEIR FAMILIES: CLINICAL UTILITY OF JOINT INTERDISCIPLINARY OUTPATIENT CONSULTATIONS
Ulrike Leiss

P9 PSYCHOMETRIC VALIDATION OF THE PAIN INTENSITY SCALE FOR PLEXIFORM NEUROFIBROMAS TARGET PLEXIFORM NEUROFIBROMA PAIN SEVERITY SCORE USING DATA FROM KOMET (NCT04924608)
Ayo Adeyemi

P10 SOCIAL RESPONSIVENESS IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND ASSOCIATION WITH ATTENTION AND EXECUTIVE FUNCTIONING
Mary Anne Toledo-Tamula

P11 REAL-WORLD MENTAL HEALTH MEDICATION UTILIZATION PRE- AND POST-SELUMETINIB INITIATION AMONG ADULT PATIENTS IN THE US: A RETROSPECTIVE CLAIMS DATABASE STUDY
Justin Jordan

P12 PSYCHOMETRIC VALIDATION OF NOVEL PATIENT-REPORTED OUTCOME (PRO) MEASURES TO ASSESS PLEXIFORM NEUROFIBROMA (PNF) PAIN INTENSITY AND PAIN INTERFERENCE IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (Nf1)
Pamela L. Wolters

P13 AGE-RELATED ATTENTION PROFILES IN NEUROFIBROMATOSIS TYPE 1: A CROSS-SECTIONAL STUDY OF 1016 INDIVIDUALS
Charlotte Münch

P14 HEALTH-RELATED QUALITY OF LIFE ISSUES FACED BY ADULTS WITH NEUROFIBROMATOSIS TYPE 1: A SCOPING REVIEW
Sarah Van Dijk

P15 EVALUATION OF A SPECIALIST NEUROFIBROMATOSIS SOCIAL WORK SERVICE: PATIENT-REPORTED OUTCOMES FROM A UK NATIONAL CENTRE
Isha Kallay

P16 HANDWRITING DEFICITS IN CHILDREN WITH NF1: EVIDENCE FROM RETROSPECTIVE AND PROSPECTIVE ASSESSMENTS
Fy-Tahina Barijaona

P17 A CLINICAL SERVICE EVALUATION: NEURODEVELOPMENTAL AND MENTAL HEALTH CONDITIONS IN CHILDREN AND YOUNG PEOPLE WITH NF2-RELATED SCHWANNOMATOSIS
Grace Vassallo

P18 PAIN ASSESSMENT IN POPULATIONS WITH VARIED COMMUNICATION NEEDS
Heather L. Thompson

Posters related to **Basic Session 1: Preclinical Models for Neurofibromatosis Type 1 and Schwannomatosis Pathogenesis**

P19 INVESTIGATING EARLY BRAIN TUMOR DEVELOPMENT IN NF1: INSIGHTS FROM PATIENT-DERIVED WHOLE BRAIN ORGANOIDS AND A THREE-GENERATION FAMILY WITH VARIABLE PHENOTYPES
Pavle Zivanovic

P20 TAUT A CELL TO TRANSPORT FED IT FOR A LIFETIME ROLE OF SLC6A6 ON METABOLISM AND PROLIFERATION IN MPNST CELLS
Aidan Robinson

P21 NULL NF1 PHENOTYPE IN A CARRIER OF A LARGE NF1 DELETION DUE TO MOSAICISM
Lan Kluwe

P22 DEEP-SEATED HUMAN CUTANEOUS NEUROFIBROMAS DISPLAY DECREASED T CELL INFILTRATION: AN ANALYSIS OF BETWEEN-TUMOR VARIATION
Roope Kallionpää

Poster related to **Clinical Session 2 (Joint with Basic Science) - Bone and Orthopaedic Aspects of Nf1**

P23 DEBULKING PLEXIFORM NEUROFIBROMAS TO FACILITATE HIP ARTHROPLASTY IN NEUROFIBROMATOSIS TYPE 1: LESSONS LEARNED FROM A COLLABORATIVE SURGICAL APPROACH
Lucy Homer Newton

Poster related to **Basic Session 2: Basic Biology underlying Neurofibromatosis Type 1 and Schwannomatosis**

P25 UNDERSTANDING HOW MERLIN SHAPES SCHWANN CELL BEHAVIOUR AND HETEROGENEITY IN NF2-RELATED VESTIBULAR SCHWANNOMA
Omar Ahmid

Poster related to **Clinical Session 3: Visible Manifestations in Neurofibromatosis**

P26 EVALUATION OF DERMATOLOGICAL MANIFESTATIONS AND THEIR IMPACT ON THE DAILY LIVES OF NF1 PATIENTS UNDERGOING SELUMETINIB TREATMENT – A DESCRIPTIVE QUANTITATIVE STUDY
Mafalda Ferreira

Posters related to **Basic Session 3: Basic and Translational Research in Schwannomatosis: Selected from Abstracts**

P27 DECIPHERING THE MOLECULAR LANDSCAPE OF SPORADIC AND SYNDROME-ASSOCIATED HYBRID NEUROFIBROMA-SCHWANNOMA
Lucy Lissow

P28 PAN-RAS AND TEAD INHIBITION COOPERATIVELY SUPPRESS SCHWANNOMA GROWTH
Qian Chen

Posters related to **Plenary 2: Together - Patient Involvement in Research and Clinic**

P29 ADULT PATIENTS' EXPERIENCES WITH SELUMETINIB TREATMENT VERSUS PLACEBO FOR NEUROFIBROMATOSIS TYPE 1-PLEXIFORM NEUROFIBROMA-ASSOCIATED SYMPTOMS AND THEIR IMPACTS: A QUALITATIVE SUB-STUDY OF A PHASE 3, PLACEBO-CONTROLLED TRIAL (KOMET)
Ignacio Blanco

P30 BARRIERS TO TIMELY ACCESS TO SELUMETINIB FOR CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 IN A RESOURCE-LIMITED SETTING: A REAL-WORLD SINGLE-CENTER EXPERIENCE
Nonato Mendonça Lott Monteiro

P31 BUILDING A NATIONAL NF SUPPORT NETWORK ACROSS THE UK : AN INNOVATIVE CHARITY - NHS PARTNERSHIP MODEL FOR NF1, NF2- RELATED SCHWANNOMATOSIS AND SCHWANNOMATOSIS
Helen Tomkins

P32 IMPROVING THE EXPERIENCE OF HOSPITAL OUTPATIENT DEPARTMENTS FOR NEUROFIBROMATOSIS PATIENTS WITH SENSORY CHALLENGES USING EXPERIENCE BASED CO-DESIGN: A STUDY PROTOCOL
Rona Inniss

P33 PATIENT AND FAMILY INVOLVEMENT IN MULTIDISCIPLINARY CARE FOR NEUROFIBROMATOSIS TYPE 1-ASSOCIATED TUMORS: THE MEYER CHILDREN'S HOSPITAL EXPERIENCE
Mara Cavallin

P34 HOW DO STAFF AND PATIENTS EXPERIENCE THE BUILT ENVIRONMENT OF A CONTEMPORARY OUTPATIENT DEPARTMENT? A SYSTEMATIC REVIEW OF QUALITATIVE EVIDENCE
Rona Inniss

Posters related to **Plenary 3 - Part 1:**
Pexiform Neurofibroma

P35 DISEASE BURDEN AND HEALTHCARE UTILIZATION AFTER DIAGNOSIS OF NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS IN SWEDISH ADULT PATIENTS: A REGISTRY-BASED STUDY
Bjorn Sigurdsson

P36 DISEASE BURDEN AND HEALTHCARE UTILIZATION AFTER DIAGNOSIS OF NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS IN SWEDISH PEDIATRIC PATIENTS: A REGISTRY-BASED STUDY
Bjorn Sigurdsson

P37 NATURAL HISTORY, MANAGEMENT AND BURDEN OF DISEASE IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1 AND SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN FRANCE
Laura Fertitta

P38 DESCRIPTION OF THE CHARACTERISTICS AND BURDEN OF NEUROFIBROMATOSIS TYPE 1 WITH PLEXIFORM NEUROFIBROMA IN A SAMPLE OF ADULT PATIENTS IN JAPAN: RESULTS FROM A REAL-WORLD SURVEY
Yoshihiro Nishida

P39 CLINICAL AND HUMANISTIC BURDEN OF ADULT PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 WITH PLEXIFORM NEUROFIBROMA IN THE REAL-WORLD SETTING ACROSS FOUR EUROPEAN COUNTRIES: RESULTS FROM A REAL-WORLD SURVEY
Ignacio Blanco

P40 DESCRIPTION OF THE CHARACTERISTICS AND BURDEN OF NEUROFIBROMATOSIS TYPE 1 WITH PLEXIFORM NEUROFIBROMA IN A SAMPLE OF ADULT PATIENTS IN CHINA: RESULTS FROM A REAL-WORLD SURVEY
Ayo Adeyemi

P41 PLEXIFORM NEUROFIBROMAS: CLINICAL EXPERIENCE OF SINGLE SPECIALIST PAEDIATRIC NF1 SERVICE
Jamuna Acharya

P42 EXPERIENTIAL OBSERVED CHANGES IN THE CHARACTERISTICS OF CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) BEING PUT FORWARD AND APPROVED FOR MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS (MEKI) IN THE NORTH OF ENGLAND
Carol Irving

Posters related to **Plenary 3 - Part 2:**
Malignant Progression from Neurofibroma to MPNST

P43 HIGH-DEPTH CFDNA PROFILING IN NEUROFIBROMATOSIS TYPE 1: A PILOT STUDY ON SOMATIC VARIANT DETECTION ACROSS TUMOR STAGES
Federica Chiara

P44 PLEXIFORM NEUROFIBROMAS AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1: CLINICAL INSIGHTS FROM A LARGE COHORT
Walter Taal

P45 PEDIATRIC MPNST AND PRECURSOR LESIONS - A CASE SERIES
Thomas Brückner

P46 CAUTION IN MANAGEMENT OF PLEXIFORM NEUROFIBROMAS IN ASPECTS OF MALIGNANT TRANSFORMATION: SINGLE CENTRE EXPERIENCE
Iuliia Dinikina

Posters related to **Clinical Session 4:**
SWN Basket Session (Pain, Hybrid Tumours, etc.)

P47 A MULTICENTER REGISTRY FOR SCHWANNOMATOSIS AND NEUROFIBROMATOSIS (RFNS) – DATA PROTECTION, INCENTIVE CREATION, STEERING
Steffen K. Rosahl

P48 MOLECULAR DIAGNOSTIC OF SCHWANNOMATOSIS: A SINGLE CENTRE EXPERIENCE
Roberta Palmitessa

P49 QUALITY OF LIFE AND READINESS FOR END OF LIFE COMMUNICATION IN NEUROFIBROMATOSIS TYPE 2 RELATED SCHWANNOMATOSIS
Daniel Muñoz Pérez

P50 EMBEDDING SPEECH AND LANGUAGE THERAPY WITHIN THE NF2-SWN MULTIDISCIPLINARY TEAM
Eleanor Dixon

P51 REGISTRY NFS: A MULTICENTER REGISTRY FOR NEUROFIBROMATOSIS AND SCHWANNOMATOSIS – PURPOSE AND DEVELOPMENT
Lan Kluwe

P52 CROSS CULTURAL ADAPTATION AND VALIDATION OF THE SPANISH NEUROFIBROMATOSIS TYPE 2 IMPACT ON QUALITY OF LIFE QUESTIONNAIRE (Es-NFTI-QoL)
Daniel Muñoz Pérez

Posters related to **Basic Session 4: Basic and Translational Research in Neurofibromatosis Type 1: Selected from Abstracts**

P53 PRECLINICAL EVALUATION OF COMBINED cAMP PATHWAY ACTIVATION AND MEK INHIBITION IN CUTANEOUS NEUROFIBROMAS
Helena Mazuelas

P54 CRISPR-CAS9 FUNCTIONAL SCREEN FOR CANDIDATE MODIFIER GENES IN NEUROFIBROMAS
Laurence Pacot

Posters related to **Plenary 4: CNS Tumours in Neurofibromatosis Type 1 and Schwannomatosis**

P55 THE MANY FACES OF TECTAL PLATE GLIOMAS IN PAEDIATRIC NEUROFIBROMATOSIS TYPE 1
Hiya Khandelwal

P56 OPTIC PATHWAY GLIOMAS: CLINICAL EXPERIENCE OF SINGLE SPECIALIST PAEDIATRIC NF1 SERVICE
Jamuna Acharya

P57 NATURAL HISTORY OF FOCAL AREAS OF SIGNAL INTENSITY AND THEIR RELATIONSHIP TO NON-OPTIC GLIOMAS IN NEUROFIBROMATOSIS TYPE 1
Kaleb Yohay

P58 OUTCOMES OF VESTIBULAR SCHWANNOMA SURGERY IN NF2-RELATED SCHWANNOMATOSIS
Michel Kalamarides

P59 LONG-TERM OUTCOME OF BEVACIZUMAB TREATMENT OF A LARGE COHORT OF Nf2-SCHWANNOMATOSIS PATIENTS: A SINGLE-CENTER EXPERIENCELONG-TERM OUTCOME OF BEVACIZUMAB TREATMENT OF A LARGE COHORT OF NF2-SCHWANNOMATOSIS PATIENTS: A SINGLE-CENTER EXPERIENCE
Elizabeth Makashova

P60 HEARING OUTCOMES AND SAFETY OF BEVACIZUMAB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 RELATED TUMORS
Carla Fonte

P61 TREATMENT WITH MEK-INHIBITORS IN PATIENTS WITH LOW GRADE GLIOMAS IN NEUROFIBROMATOSIS TYPE 1: A SINGLE CENTER EXPERIENCE
Carla Fonte

Posters related to **Clinical Session 5: Imaging in Neurofibromatosis / SWN**

P62 COST-EFFECTIVENESS OF TOTAL-BODY MRI SCREENING FOR NF1-PN: A GLOBAL COMPARATIVE STUDY
Zhichao Wang

P63 MRI-BASED LONG-TERM EVALUATION ON THE CHARACTERISTICS, DEVELOPMENT, AND GROWTH OF DISTINCT NODULAR LESIONS IN PATIENTS WITH NF1 ON WHOLE-BODY MRI
Dilara Kisir

Posters related to **Basic Session 5: Genomics and Bioinformatics for Neurofibromatosis Type 1 and Schwannomatosis**

P64 INVESTIGATING BIOLOGICAL DIFFERENCES BETWEEN CUTANEOUS AND PLEXIFORM NEUROFIBROMAS AT SINGLE CELL RESOLUTION
Miriam Magallón-Lorenz

P65 IDENTIFYING MHC CLASS I TARGETS IN NEUROFIBROMATOSIS TYPE 1-ASSOCIATED TUMORS
Danae McCulloch

Posters related to **Clinical Session 6:**
Rare / Miscellaneous Manifestations

P66 MULTIDISCIPLINARY MANAGEMENT OF PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 AT THE DMITRY ROGACHEV NATIONAL MEDICAL RESEARCH CENTER
Anastasiya Salomatina

P67 A CLINICAL AND ELECTROPHYSIOLOGICAL STUDY OF NF2-SCHWANNOMATOSIS ASSOCIATED POLYNEUROPATHY. A SINGLE RETROSPECTIVE CASE SERIES
Tim Lavin

P68 CAUGHT IN UTERO: A RARE CASE OF AN ANTENATALLY DETECTED PLEXIFORM NEUROFIBROMA
Grace Vassallo

P69 CLINICAL AND MOLECULAR CHARACTERISTICS OF GASTROINTESTINAL STROMAL TUMOURS IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1
Ana Blatnik

P70 BEYOND THE OPTIC PATHWAY: CEREBELLAR ANOMALIES AS AN UNDERDIAGNOSED FEATURE OF NEUROFIBROMATOSIS TYPE 1
Chiara Canciani

P71 JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) IN NEUROFIBROMATOSIS TYPE 1 (NF-1): THREAT, INFREQUENCY OR COINCIDENCE? SINGLE CENTER EXPERIENCE IN THE CONTEXT OF LITERATURE REAL-WORLD DATA
Marek Karwacki

P72 OBSTRUCTIVE HYDROCEPHALUS IN PEDIATRIC NEUROFIBROMATOSIS TYPE 1: TWO CASES HIGHLIGHTING DISTINCT MECHANISMS AND MANAGEMENT CHALLENGES
Herta Zellner

P73 EPILEPTIFORM EEG ABNORMALITIES IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1: HIGH PREVALENCE, SPONTANEOUS RESOLUTION, AND LIMITED ASSOCIATION WITH EPILEPSY
Germana Lo Monaco

P74 DIAGNOSED PREVALENCE OF NEUROFIBROMATOSIS TYPE 1 IN THE UNITED STATES FROM 2020 TO 2024
Miriam Bornhorst

P75 AUXOLOGICAL DATA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH NEUROFIBROMATOSIS TYPE 1 IN AUSTRIA
Nicolas Wschiansky

P76 A 15 YEAR REVIEW OF ONE OF THE TWO SPECIALIST NEUROFIBROMATOSIS SERVICES IN THE UK: A REVIEW OF THE SERVICE AND HEAT MAPPING OF REFERRALS
Lucy Homer Newton

P77 NATIONWIDE INPATIENT ACTIVITY FOR NEUROFIBROMATOSIS IN GERMANY, 2019 TO 2024: A DESCRIPTIVE ANALYSIS OF §21 HOSPITAL ADMINISTRATIVE DATA
Aaron Lawson McLean

P78 THE USE OF LARGE LANGUAGE MODELS TO REVIEW INTERNATIONAL APPROACHES TO NEUROFIBROMATOSIS AND SCHWANNOMATOSIS GUIDELINES
Amedeo Azizi

P79 NEUROFIBROMATOSIS TYPE 1 (NF1) IN SCOTLAND: A SURVEY OF GENERAL PRACTITIONER CONFIDENCE
Sheelagh Harwell

P80 A LIFESPAN SHARED CARE FRAMEWORK FOR NEUROFIBROMATOSIS TYPE 1 IN SETTINGS WITHOUT DEDICATED CLINICS
Ivan Bogdanović

P81 CLINICAL SPECTRUM AND MULTIDISCIPLINARY FOLLOW-UP OF CHILDREN AND ADOLESCENTS WITH NEUROFIBROMATOSIS TYPE 1
Andreia Forno

P82 AN ADULT MULTIDISCIPLINARY CLINIC IN CANADA: MODEL OF CARE AND CLINICAL INTEGRATION
Katie Cardiff

Poster related to **Basic Session 6: AI and Big Data in Neurofibromatosis Type 1 and Schwannomatosis Research**

P83 PRIVATE EYES USING ALPHAGENOME TO SHED LIGHT ON THE NF1 GENOTYPE PHENOTYPE CORRELATION
Neil Matthews

Posters related to **Plenary 5: New Therapeutic Developments - Future Clinical Trials and Clinical Trial Design - Preclinical Drug Development – Part 2**

P84 TIME LIMITED ADD-ON OF VINBLASTINE TO TARGETED THERAPY WITH SELUMETINIB FOR NF1 ASSOCIATED PEDIATRIC LOW-GRADE GLIOMA – A PHASE 2 STUDY PROPOSAL
Julia Grosser

P85 THE FIRST CLINICAL CASE OF MIRDAMETINIB TREATMENT IN THE RUSSIAN FEDERATION AT 1-YEAR OLD CHILD WITH AN UNRESECTABLE PLEXIFORM NEUROFIBROMA OF THE ORBIT ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1
Anastasiya Salomatina

P86 SAFETY, TOLERABILITY, AND EFFICACY OF TQ-B3234 IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (Nf1): AN OPEN-LABEL PHASE 1 DOSE-ESCALATION AND DOSE-EXPANSION TRIAL AND EXPLORATORY ANALYSIS
Zhichao Wang

P87 EXPOSURE-RESPONSE ANALYSES BASED ON THE SPRINKLE STUDY TO VALIDATE THE RECOMMENDED DOSING OF SELUMETINIB GRANULAR FORMULATION IN CHILDREN AGED FROM 1 TO LESS THAN 7 YEARS WITH NEUROFIBROMATOSIS TYPE 1 AND SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS
Salvador Fudio

P88 POPULATION PHARMACOKINETICS AND EXPOSURE–RESPONSE ANALYSES OF SELUMETINIB IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1 AND SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS IN THE KOMET STUDY (NCT04924608)
Salvador Fudio

P89 A DIGITAL PATIENT NAVIGATION AND LONGITUDINAL MONITORING PLATFORM INTEGRATING RICCARDI-SCORE-BASED DECISION SUPPORT FOR NEUROFIBROMATOSIS TYPE 1: A PROSPECTIVE OBSERVATIONAL STUDY DESIGN
Celia Blasszauer

P90 FINAL ANALYSIS OF KOMET, A PHASE 3 STUDY OF SELUMETINIB IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS
Alice Chen

P92 A REAL-WORLD, MULTIPLE-COUNTRY, PROSPECTIVE COHORT POST-AUTHORISATION SAFETY STUDY OF SELUMETINIB IN PAEDIATRIC PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 AND SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS: AN INTERIM ANALYSIS
Thomas Rosenbaum

P93 THE REAL-WORLD EFFECTIVENESS AND SAFETY OF SELUMETINIB IN CHINESE PEDIATRIC PATIENTS WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS (NF1-PN)
Fanni Peng

P94 DISEASE BURDEN OF NEUROFIBROMATOSIS TYPE 1 AND ASSOCIATED PLEXIFORM NEUROFIBROMAS: RESULTS FROM THE PROMISE COHORT STUDY
Zhichao Wang

P95 THE DURABLE IMPACT OF SELUMETINIB THERAPY IN CHILDREN AND YOUNG PEOPLE WITH SYMPTOMATIC INOPERABLE NF1-RELATED PLEXIFORM NEUROFIBOMA; A SINGLE-CENTRE EXPERIENCE WITH UP TO 8 YEARS FOLLOW-UP
Karina Forde

P96 PAS-004-103: A PHASE 1/1b STUDY TO ASSESS THE SAFETY, TOLERABILITY PHARMACOKINETICS AND CLINICAL ACTIVITY OF PAS-004, A MACROCYCLIC MEK INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH NF1-ASSOCIATED PLEXIFORM NEUROFIBROMA (pNF)
Rebecca Brown

P97 USE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR WEIGHT MANAGEMENT IN NEUROFIBROMATOSIS TYPE 1 (Nf1)
Mary Thomas

P98 SMALL PATIENTS, BIG DECISIONS: MEK INHIBITORS IN EARLY CHILDHOOD - PROMISES, PITFALLS, AND PERSPECTIVES
Pia Vaassen

2026 European NF Conference



Living with neurofibromatosis is a daily reality — even when you can't always see it!

Make a difference. Help us defeat NF through research and give children with NF hope for a cure.

Donate at www.nfkinder.at

NF Kinder
Neurofibromatose durch Forschung besiegen

ÖSTERREICHISCHES SPENDEN GÜTESIEGEL 06327 WWW.OSGS.AT

Sponsors

We thank our sponsors for their generous support of the conference!

Platinum Sponsor

ALEXION
AstraZeneca Rare Disease

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

www.alexion.com

Platinum Sponsor

MERCK

Guided by our purpose, we work As One for Patients to take a holistic approach to healthcare, designing medicines and intelligent devices that support patients throughout their care journey. Our work spans oncology, rare tumors - including NF1-PN, desmoid tumors, and tenosynovial giant cell tumor (TGCT), multiple sclerosis, and fertility, alongside digital tools and biomarker-driven approaches that help personalize care.

In rare tumors, we are on a mission to improve patient lives, grounded in urgency and scientific rigor, to focus on outcomes that matter most to patients and impact their realities.

www.merckgroup.com/en/expertise/rare-tumors.html

Bronze Sponsor

pasithea THERAPEUTICS

www.pasithea.com

Pasithea Therapeutics is a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (Nf1). Pasithea is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

Sponsors

CERENEF

www.cerenef.org

CHILDREN'S TUMOR FOUNDATION
ENDING NF THROUGH RESEARCH

www.ctf.org

EUROPEAN NF GROUP

www.enfg.eu

healx

www.healx.ai


Industry Exhibition

The Industry Exhibition is located in the foyers of the conference area.
The Opening hours are as following:

Thursday, November 12	12:00 – 21:00
Friday, November 13	07:00 – 18:00
Saturday, November 14	08:00 – 18:00

Our exhibitors look forward to meeting you at their booth for fruitful talks!

Venue & Exhibition Floorplan



A ALEXION AstraZeneca Rare Disease

B MERCK

C pasithea THERAPEUTICS

D NF Kinder

NF Patients United



Koselugo▼
(selumetinib)
10 mg & 25 mg capsules
5 mg & 7.5 mg oral granules

KOSELUGO, the first approved therapy for symptomatic, inoperable NF1-PN, is a proven effective and tolerable treatment to support your paediatric and adult patients[1–4]

Available in capsule and granule formulations for patients with swallowing difficulties[2]

KOSELUGO in NF1-PN is supported by 7.7 years of clinical research across paediatric and adult populations and more than 5 years of real-world experience in paediatric populations*[2–5]

KOSELUGO as monotherapy is indicated for the treatment of symptomatic, inoperable PN in adult and paediatric patients with NF1 aged 3 years and older.[2]

KOSELUGO granules in capsule as a monotherapy is indicated for the treatment of symptomatic, inoperable PN in patients with NF1 aged 1 year to <7 years and for older patients with swallowing difficulties.[2]

This product has a conditional marketing authorisation. Further evidence on this medical product is awaited.

▼This medical product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please report any AEs via your national reporting system. AEs can also be reported to AstraZeneca by visiting https://aereporting.astrazeneca.com

*KOSELUGO has been clinically studied for >7 years in the SPRINT trial in paediatric patients and for approximately 2.1 years in the KOMET trial in adults.[2–4] Five years of real-world experience since FDA approval in 2020.[5]

AE, adverse event; FDA, US Food and Drug Administration; NF1, neurofibromatosis type 1; NF1-PN, plexiform neurofibromas associated with neurofibromatosis type 1; PN, plexiform neurofibromas.

1. Fisher MJ et al. *Neuro Oncol* 2022;24:1827–1844; **2.** AstraZeneca AB. KOSELUGO® (selumetinib) Summary of Product Characteristics. 2026; **3.** Gross AM et al. *Neuro Oncol* 2023;35:1883–1894; **4.** Chen AP et al. *Lancet* 2025;405:2217–2230; **5.** FDA. https://web.archive.org/web/20251214133408/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas (accessed October 2026)

FACHKURZINFORMATION

▽Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Hinweise zur Meldung von Nebenwirkungen, siehe Abschnitt 4.8 der Fachinfomation.

BEZEICHNUNG DES ARZNEIMITTELS: Koselugo 10 mg Hartkapseln. Koselugo 25 mg Hartkapseln

Pharmakotherapeutische Gruppe: antineoplastische Mittel, Proteinkinase-Inhibitoren

ATC Code: L01EE04

QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG: Koselugo 10 mg Hartkapseln: Jede Hartkapsel enthält 10 mg Selumetinib (als Hydrogensulfat).

Koselugo 25 mg Hartkapseln: Jede Hartkapsel enthält 25 mg Selumetinib (als Hydrogensulfat).

Sonstige Bestandteile:

Kapselinhalt: Tocofersolan (Vitamin-E-Polyethylenglycolsuccinat / d-alpha-Tocopherol-polyethylenglycol-1000-succinat).

Kapselhülle

Koselugo 10 mg Hartkapseln: Hypromellose (E464); Carrageen (E407); Kaliumchlorid (E508); Titandioxid (E171); Carnaubawachs (E903)

Koselugo 25 mg Hartkapseln: Hypromellose (E464); Carrageen (E407); Kaliumchlorid (E508); Titandioxid (E171); Indigocarmin-Aluminiumsalz (E132); Eisen(III)-hydroxid-oxid x H2O (E172); Carnaubawachs (E903); Maisstärke

Drucktinte: Koselugo 10 mg Hartkapseln; Schellack (E904); Eisen(II,III)-oxid (E172); Propylenglycol (E1520); Ammoniak-Lösung (E527)

Koselugo 25 mg Hartkapseln: Eisen(III)-oxid (E172); Eisen(III)-hydroxid-oxid x H2O (E172); Indigocarmin-Aluminiumsalz (E132); Carnaubawachs (E903); Schellack (E904); Glycerylmonooleat

ANWENDUNGSGEBIETE: Die Koselugo-Monotherapie ist bei Kindern ab 3 Jahren, Jugendlichen und Erwachsenen zur Behandlung von symptomatischen, inoperablen plexiformen Neurofibromen (PN) bei Neurofibromatose Typ 1 (NF1) indiziert.

GEGENANZEIGEN: Überempfindlichkeit gegen den Wirkstoff oder einen der in Abschnitt 6.1 der Fachinformation genannten sonstigen Bestandteile.
Schwere Einschränkung der Leberfunktion (siehe Abschnitte 4.2 und 5.2 der Fachinformation).

INHABER DER ZULASSUNG: AstraZeneca AB, SE 151 85 Södertälje, Schweden

REZEPTPFLICHT/APOTHEKENPFLICHT: Rezept- und apothekenpflichtig, wiederholte Abgabe verboten

STAND DER INFORMATION: 10/2025. Informationen zu den Abschnitten besondere Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit, Nebenwirkungen sowie den Gewöhnungseffekten sind der veröffentlichten Fachinformation (z. B. Austria Codex) zu entnehmen.

ALEXION® is a registered trademark of the AstraZeneca group of companies. © 2026 Alexion Pharmaceuticals, Inc. All rights reserved.

AT-18504 | Date of preparation: October 2026

ALEXION®
AstraZeneca Rare Disease



We look forward to welcoming you at Booth B

The first* MEKi, approved for both pediatric and adult patients[1,2]

EZMEKLY®
(mirdametinib)
1 mg dispersible tablets / 1 mg and 2 mg capsules

THE MEK INHIBITOR THAT DELIVERED

DEEP RESPONSE† WITH ROBUST AND DURABLE CONTROL‡ IN ADULTS AND CHILDREN WITH NF1-PN[3,4]

Actor portrayal. Not indicative of medicine's efficacy.

EZMEKLY®▽ as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients with neurofibromatosis type 1 (NF1) aged 2 years and above.[1]

▽This medical product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

*The first that was approved simultaneously for both adults and children.[1,2] †Deep response is defined as best percentage reduction in target PN volume of >50% from baseline, which was achieved by 62% (15 of 24) and 52% (15 of 29) of adults and children who achieved a confirmed objective response, respectively.[3] Deep response was not a pre-specified endpoint in ReNeu. ‡Robust and durable control is defined as a combination of 1. the objective response of a ≥20% reduction in tumor volume, which was achieved by 41% (n=24; 95% CI: 29 to 55, p<0.001 vs. the predefined minimum clinically relevant response rate [23%]) of adults and 52% (n=29; 95% CI: 38 to 65, p<0.001 vs. the predefined minimum clinically relevant response rate [20%]) of children; 2. the median best percentage change in target PN volume, which was -41% (range, -90 to 13) in adults and -42% (range, -91 to 48) in children; 3. the median duration of response which was not reached in adults or children; 4. change in worst tumor pain severity (NRS-11), PII, and HRQoL (PedsQL total score), which were: LS mean change -1.3; SE, 0.2; p<0.001, -0.7; SE, 0.2; p<0.001, and 3.9; SE, 1.6; p=0.02 for adults, respectively and -0.8; SE, 0.2; p=0.003, -0.5; SE, 0.2: p=0.02, and (parent proxy) 5.6; SE, 1.9; p=0.005 in children, respectively.[3]

CI: confidence interval; HRQoL: health-related quality of life; LS: least squares; MEK: mitogen-activated protein kinase kinase; NF1: neurofibromatosis type 1; NRS: numeric rating scale; PedsQL: pediatric quality of life inventory; PII: pain interference index; PN: plexiform neurofibromas; SE: standard error.

References: 1. EZMEKLY® (mirdametinib). EU Summary of Product Characteristics. Merck Europe B.V. September 2026; **2.** Hoy SM. Drugs. 2025;85(7):977–984; **3.** Moertel C, et al. J Clin Oncol. 2025;43(6):716–729; **4.** Oztosun G, et al. Expert Opin Investig Drugs. 2025;34(9):665–673.

EZMEKLY® has received marketing authorization exclusively in the EU (conditional) and USA. A printed copy of the Summary of Product Characteristics is available at the booth. Before prescribing the product, always refer to the Prescribing Information available in your country. Please check the commercialization status as this may vary from country to country.

GL-EZM-00110 | October 2026

EMA approved Summary of Product Characteristics in English

© 2026 Merck Healthcare KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved.
EZMEKLY® is a registered trademark. All other trademarks are the property of their respective owners.

Merck

Industry Symposia

The following Industry Symposia will be organised by our Platinum Sponsors.
All congress participants are invited to join those symposia!

Industry Symposium 1 organised by Alexion, AstraZeneca Rare Disease

Friday, November 13, 2026
12:00-13:00
Lecture Hall 1 + 2 combined

Clinical evidence and expert insights on the management of NF1-PN

Dr. Said Farschtschi, Universitätsklinikum Hamburg-Eppendorf
Dr. João Passos, Instituto Português De Oncologia De Lisboa Francisco Gentil, E.p.e.
Chair: Dr. Alice Chen, National Cancer Institute

Industry Symposium 2 organised by MERCK

Date: Saturday, November 14, 2026
Time: 12:00-13:00
Lecture Hall 1 with overflow into Lecture Hall 2

CARE FOR RARE: NF1-PN management in practice: a focus on pain, evidence, and clinical cases.

Andrea Franson, University of Michigan, Ann Arbor, USA
Dusica Babovic-Vuksanovic, Mayo Clinic, Rochester, USA
Chair: Ignacio Blanco, Germans Trias i Pujol University Hospital, Barcelona, Spain

Bryter.

The insights and consultancy agency.

Share Your Perspective on NF1-PN Care in Europe

Your voice and experience will add to the conversation.

Take our anonymous 5-minute survey to share your views on the future of NF1-PN care in Europe. Patients, caregivers, clinicians, researchers, advocates and industry partners are all invited to participate.

What matters most for the future of NF1-PN care?

Scan the QR code to take the survey now or visit the URL below.

bryter-nf1-pn-survey.com

Attending the 2026 European NF Conference:

Vicky Davies
victoria.davies@bryter-global.com
www.bryter-global.com

Notes

2026 European NF Conference

12-14 November,
Vienna, Austria
EuNF2026Vienna.com

Patient involvement in Neurofibromatosis care and research

In case of any questions, please do not hesitate to contact the EUNF Team at the onsite registration desk!



Enjoy the 2026 European NF Conference!